- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00160589
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
December 13, 2013 updated by: UCB Pharma
A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)
Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
729
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season.
- A skin test for grass pollens positive:
- Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6.
Exclusion Criteria:
- Have an associated asthma requiring corticosteroid treatment,
- Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
---|
Clinical efficacy over the first and over two weeks of treatment measured by symptoms (scored and individuals); Onset of action; Safety
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2005
Primary Completion (Actual)
September 1, 2005
Study Completion (Actual)
September 1, 2005
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
December 16, 2013
Last Update Submitted That Met QC Criteria
December 13, 2013
Last Verified
September 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Levocetirizine
Other Study ID Numbers
- A00401
- LEADER
- EudraCT2004-002823-42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhinitis, Allergic, Perennial
-
UCB PharmaCompletedRhinitis | Allergic | Perennial
-
United Allergy ServicesCompletedPerennial Allergic Rhinitis With Seasonal VariationUnited States
-
Eli Lilly and CompanyNot yet recruitingPerennial Allergic Rhinitis (PAR)United States
-
Teva Branded Pharmaceutical Products R&D, Inc.United BioSource, LLCCompletedEffectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis (BALANCE)Perennial Allergic Rhinitis (PAR)United States
-
UCB PharmaCompletedRhinitis | Allergic | Perennial
-
SanofiCompleted
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
Clinical Trials on Levocetirizine
-
Hospices Civils de LyonCompletedChronic Spontaneous Urticaria
-
UCB PharmaCompleted
-
Brian J LipworthCompletedAllergic RhinitisUnited Kingdom
-
GlaxoSmithKlineZensei Pharmaceutical Co., Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
HK inno.N CorporationUnknownPerennial Allergic Rhinitis
-
UCB PharmaCompleted
-
University Hospital, GrenobleRecruiting
-
Dr. Reddy's Laboratories LimitedCompleted